What does sermorelin actually do?
Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that triggers the pituitary gland to secrete growth hormone (GH). Sermorelin does not introduce exogenous GH into the body. Instead, it stimulates the pituitary’s own secretory capacity, encouraging the natural pulsatile release pattern that declines with age.
The clinical rationale for sermorelin is that it works with the body’s existing feedback loop. If the pituitary responds — and labs showing rising IGF-1 levels confirm that it does — the protocol is working. If not, the clinician adjusts dose or reconsiders the indication. Sermorelin is compounded in the USA by licensed 503A pharmacies and is available only under clinician prescription.
Sermorelin is a Tier 1 peptide at PepScribe — meaning it has an established regulatory pathway and is commercially available through licensed 503A compounding pharmacies. Learn more about how sermorelin works.
What does testosterone therapy do?
Testosterone replacement therapy (TRT) addresses documented testosterone deficiency — low total or free testosterone confirmed by blood work, combined with symptoms like fatigue, reduced libido, difficulty maintaining muscle mass, or mood changes. Testosterone is an FDA-approved medication available in injectable, topical, and pellet forms. Compounded testosterone is also available through 503A pharmacies when clinically indicated.
Unlike sermorelin, testosterone replacement introduces the hormone directly rather than stimulating endogenous production. This means it works via a different axis and carries a distinct monitoring profile: hematocrit, PSA (for men), and testosterone blood levels are checked regularly to keep values in the therapeutic range without overshoot.
Why do sermorelin and testosterone come up together in clinical practice?
Growth hormone and testosterone are related but distinct axes. Research from the 1990s onward has documented bidirectional interactions: growth hormone supports testosterone synthesis in Leydig cells, and testosterone influences GH secretion and IGF-1 levels. In men with documented deficiency of both hormones — sometimes called combined hormone deficiency — a clinician may address both simultaneously.
The most common scenario: a patient presents with fatigue, body composition changes, reduced recovery capacity, and low libido. Labs show both low-normal testosterone and suppressed IGF-1. A clinician might determine that testosterone therapy alone would address one axis while sermorelin addresses the other. This is not a standard protocol applied universally — it is an individualized clinical decision based on that patient’s specific lab picture and goals.
It is worth emphasizing: neither therapy should be started without baseline labs. Prescribing either on symptom history alone, without blood work, is not within the standard of care.
Treating two hormonal axes at once is an individualized clinical decision driven by lab values — not a standard stack, and never prescribed on symptoms alone.
What labs does a clinician review before starting sermorelin and testosterone?
A thorough intake for sermorelin and testosterone typically includes the following blood work, though the specific panel varies by clinician and patient history:
- IGF-1 (Insulin-like growth factor 1): The primary marker for growth hormone status. IGF-1 is more stable than GH itself and reflects average GH output over time.
- Total and free testosterone: Total testosterone establishes whether deficiency is present; free testosterone accounts for binding globulin (SHBG) effects.
- LH and FSH: Luteinizing hormone and follicle-stimulating hormone distinguish primary from secondary hypogonadism, which affects treatment choice.
- Hematocrit and CBC: Testosterone can raise red blood cell count; baseline hematocrit is required and monitored throughout therapy.
- PSA (men): Prostate-specific antigen is assessed before starting testosterone therapy.
- Metabolic panel: Baseline glucose, liver enzymes, and kidney function inform risk stratification.
How is a combined sermorelin and testosterone protocol monitored?
Running two hormonal interventions simultaneously means two monitoring cadences. Sermorelin protocols typically reassess IGF-1 at 90 days and adjust dose accordingly. Testosterone monitoring happens more frequently early on — often at 6–8 weeks to check levels and hematocrit, then quarterly once stable.
A clinician managing both will time labs to catch the most clinically relevant windows for each therapy. The goal is not simply to see numbers move — it is to confirm therapeutic range without unintended effects on the other axis.
What this is not
Combining sermorelin and testosterone is not a performance-enhancing shortcut and is not appropriate for people with normal hormone levels seeking supraphysiological optimization. No outcome — body composition change, recovery speed, muscle gain — can be guaranteed, because individual response depends on baseline endocrine function, age, genetics, sleep, and lifestyle.
Compounded sermorelin is also not an FDA-approved drug. It is a 503A compounded preparation, which means it is prepared by a licensed pharmacy for an individual patient under a valid prescription. No hidden overseas supply chain. All PepScribe compounding is performed in the USA by licensed 503A pharmacies.
Frequently asked questions
Can sermorelin and testosterone be taken together?
Some clinicians supervise protocols that include both sermorelin and testosterone, typically when labs indicate low levels of both growth hormone secretion and testosterone. Each prescription requires independent clinical justification and monitoring.
Does sermorelin increase testosterone?
Sermorelin stimulates pituitary release of growth hormone — it is not a testosterone therapy. Growth hormone and testosterone do share downstream interactions in anabolic signaling, but sermorelin is not prescribed as a testosterone replacement or booster.
What labs are checked before combining sermorelin and testosterone?
A clinician typically reviews IGF-1, total and free testosterone, LH, FSH, hematocrit, PSA (for men), and a metabolic panel before considering either therapy. Baseline labs guide protocol design and ongoing monitoring.
Is testosterone a compounded medication?
Testosterone is an FDA-approved drug available in several branded forms. Compounded testosterone preparations are also available through licensed 503A pharmacies when clinically indicated, under physician prescription.
How long before results are noticeable when combining these therapies?
Sermorelin protocols are typically evaluated over three to six months, with IGF-1 levels checked at intervals. Testosterone response timelines vary. A clinician will set expectations and adjust based on lab values, not subjective impressions alone.
Who should not combine sermorelin with testosterone therapy?
Contraindications are assessed individually. History of hormone-sensitive conditions, active malignancy, untreated sleep apnea, or certain cardiovascular conditions may affect candidacy for either therapy. A full clinical intake is required.